VANTAS Drug Patent Profile

When do Vantas patents expire, and what generic alternatives are available?

Vantas is a drug marketed by Endo Operations and is included in one NDA.

The generic ingredient in VANTAS is histrelin acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the histrelin acetate profile page.

Summary for VANTAS

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	4
Patent Applications:	3,888
Drug Prices:	Drug price information for VANTAS
What excipients (inactive ingredients) are in VANTAS?	VANTAS excipients list
DailyMed Link:	VANTAS at DailyMed

See drug prices for VANTAS

Recent Clinical Trials for VANTAS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Southwest Oncology Group	Phase 3
National Cancer Institute (NCI)	Phase 3
University of Colorado, Denver	Phase 2

See all VANTAS clinical trials

US Patents and Regulatory Information for VANTAS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Operations	VANTAS	histrelin acetate	IMPLANT;SUBCUTANEOUS	021732-001	Oct 12, 2004		DISCN	Yes	No

Expired US Patents for VANTAS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Operations	VANTAS	histrelin acetate	IMPLANT;SUBCUTANEOUS	021732-001	Oct 12, 2004
Endo Operations	VANTAS	histrelin acetate	IMPLANT;SUBCUTANEOUS	021732-001	Oct 12, 2004

International Patents for VANTAS

See the table below for patents covering VANTAS around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	69217900
Australia	651654
European Patent Office	0551698	Fabrication d'articles hydrophiles hydro-gonflables et dispositifs de délivrance de médicaments (Manufacture of water - swellable hydrophilic articles and drug delivery devices)
Canada	2059377	FABRICATION D'ARTICLES HYDROPHILES GONFLANT DANS L'EAU ET DISPOSITIFS D'ADMINISTRATION DE MEDICAMENTS (MANUFACTURE OF WATER-SWELLABLE HYDROPHILIC ARTICLES AND DRUGDELIVERY DEVICES)

VANTAS Market Analysis and Financial Projection Experimental

Prostate Cancer Therapeutics Market: Focus on VANTAS

Introduction

The prostate cancer therapeutics market is a rapidly evolving sector, driven by increasing prevalence, advances in treatment options, and significant investments in research and development. One of the key drugs in this market is VANTAS, a luteinizing hormone-releasing hormone (LHRH) agonist. Here, we will delve into the market dynamics and financial trajectory of VANTAS.

Market Overview

The global prostate cancer therapeutics market was valued at USD 12.12 billion in 2022 and is projected to reach USD 21.48 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.4% from 2023 to 2030[1][4].

Drug Class: LHRH Agonists

VANTAS falls under the category of LHRH agonists, which are a crucial part of hormonal therapy for prostate cancer. These drugs work by initially stimulating the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to an increase in testosterone levels. However, with continuous administration, they downregulate LH and FSH receptors, resulting in decreased testosterone production, which is beneficial in treating prostate cancer.

Market Share and Growth

The hormonal therapy segment, which includes LHRH agonists like VANTAS, held the largest share in the prostate cancer therapeutics market. This segment is expected to be the fastest-growing due to the efficient mechanism of action and widespread availability of these drugs[1][4].

Regional Dynamics

North America dominates the prostate cancer therapeutics market, accounting for 41.1% of the revenue share in 2022. This dominance is attributed to the high prevalence of prostate cancer and a strong demand for therapeutic products in the region. The Asia Pacific region is expected to demonstrate the fastest growth, driven by cost-effective treatments, technological advancements, and an increasing incidence of prostate cancer[1][4].

VANTAS: Specific Market Dynamics

VANTAS, specifically, is a subcutaneous implant that releases histrelin acetate, an LHRH agonist, continuously over a period of 12 months. This long-acting formulation makes it a convenient option for patients, reducing the need for frequent injections.

Competitive Landscape

The market for LHRH agonists is competitive, with other drugs like Lupron, Zoladex, Eligard, and Decapeptyl also available. However, VANTAS has a unique selling point due to its implantable nature, which can improve patient compliance and reduce the burden of frequent medical visits.

Financial Performance

While specific financial data for VANTAS is not provided in the sources, the overall revenue from hormonal therapy, including LHRH agonists, is substantial. The hormonal therapy segment is expected to continue growing, driven by the demand for effective and convenient treatment options like VANTAS.

Distribution Channels

The distribution of VANTAS and other prostate cancer therapeutics is primarily through hospital pharmacies and drug stores. However, there is a rising trend towards online pharmacies, which could further enhance the accessibility of these drugs[1][4].

Regulatory and Approval Landscape

The approval and regulatory environment play a critical role in the market dynamics of drugs like VANTAS. Recent approvals of new drugs and advancements in therapeutic options, such as the FDA approval of Pluvicto in March 2022, indicate a favorable regulatory climate for innovative treatments[1].

Patient and Market Trends

The increasing awareness and preference for online drug purchasing are expected to enhance the treatment adoption rate. Additionally, government funding and public-private initiatives to raise awareness about available medicines are projected to accelerate market growth[4].

Challenges and Opportunities

Despite the growth potential, the market faces challenges such as pricing transparency and medical benefit management. Manufacturers must demonstrate innovation and differentiation to justify higher prices, and there is a growing need for outcomes-based data to support pricing decisions[3].

Key Takeaways

• Market Growth: The prostate cancer therapeutics market is expected to grow significantly, driven by increasing prevalence and demand for novel therapeutics.
• Hormonal Therapy: LHRH agonists like VANTAS are a key segment, expected to be the fastest-growing due to their efficient mechanism of action.
• Regional Dynamics: North America dominates the market, while the Asia Pacific region is expected to show the fastest growth.
• Distribution Channels: Hospital pharmacies and drug stores are primary distribution channels, with a rising trend towards online pharmacies.
• Regulatory Environment: Favorable regulatory approvals and a strong pipeline of new drugs support market growth.

FAQs

1. What is the projected growth rate of the prostate cancer therapeutics market?

   • The market is expected to grow at a CAGR of 8.4% from 2023 to 2030[1][4].

2. Which region dominates the prostate cancer therapeutics market?

   • North America dominates the market, accounting for 41.1% of the revenue share in 2022[1].

3. What is the role of LHRH agonists like VANTAS in prostate cancer treatment?

   • LHRH agonists like VANTAS reduce testosterone production, which is beneficial in treating prostate cancer[1][4].

4. How does the distribution of prostate cancer therapeutics, including VANTAS, occur?

   • The distribution is primarily through hospital pharmacies and drug stores, with a rising trend towards online pharmacies[1][4].

5. What are the key challenges facing the prostate cancer therapeutics market?

   • Challenges include pricing transparency, medical benefit management, and the need for outcomes-based data to support pricing decisions[3].

Sources

1. Grand View Research - Prostate Cancer Therapeutics Market Size Report, 2030
2. Vanda Pharmaceuticals - Reports First Quarter 2024 Financial Results
3. IQVIA - 7 Market Access Trends for 2027
4. Research and Markets - Prostate Cancer Therapeutics Market Size, Share & Trends Analysis